nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

05.09.2018 | Original Article

¹⁸F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System

verfasst von: Sung-Hoon Jung, Seong Young Kwon, Jung-Joon Min, Hee-Seung Bom, Seo-Yeon Ahn, Seung-Yeon Jung, Seung-Shin Lee, Moo-Rim Park, Deok-Hwan Yang, Jae-Sook Ahn, Hyeoung-Joon Kim, Je-Jung Lee

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study evaluated the prognostic role of ¹⁸F-FDG PET/CT at baseline in patients with newly diagnosed multiple myeloa (MM) and evaluated the prognostic relevance of ¹⁸F-FDG PET/CT for each stage according to the Revised International Staging System (R-ISS).

Method

We retrospectively analyzed the records of 167 patients with newly diagnosed MM. ¹⁸F-FDG PET/CT was performed prior to induction therapy in patients with newly diagnosed MM.

Results

In the total cohort, the presence of more than three hypermetabolic focal lesions (FLs) or extramedullary disease (EMD) on baseline PET/CT was associated with significantly inferior progression-free survival (PFS) and overall survival (OS) than other patients. Because most patients (91%) with EMD had more than three FLs, PET/CT positivity was defined as the presence of more than three FLs or the presence of EMD. In multivariate analyses, PET/CT positivity was an independent predictor of PFS and OS in all patients. Fifty-five patients (46.1%) with R-ISS II were PET/CT-positive at baseline and had significantly shorter PFS and OS. PET/CT positivity was also correlated with poor PFS and OS in patients with R-ISS III.

Conclusion

¹⁸F-FDG PET/CT was an independent predictor of survival outcomes in patients with newly diagnosed MM. In addition, performing ¹⁸F- FDG PET/CT at diagnosis may be useful for determining the survival outcomes of MM patients with R-ISS II and III.

Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–72. https://doi.org/10.1182/blood-2007-10-078022.CrossRefPubMedPubMedCentral

Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–76. https://doi.org/10.1182/blood-2012-01-405985.CrossRefPubMedPubMedCentral

Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17:543–56. https://doi.org/10.1038/nrc.2017.63.CrossRefPubMed

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100–13. https://doi.org/10.1038/nrclinonc.2016.122.CrossRefPubMed

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9. https://doi.org/10.1200/jco.2015.61.2267.CrossRefPubMedPubMedCentral

Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102:593–9. https://doi.org/10.3324/haematol.2016.145078.CrossRefPubMedPubMedCentral

Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, et al. Comprehensive evaluation of the Revised International Staging System in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol. 2017;92:1280–6. https://doi.org/10.1002/ajh.24891.CrossRefPubMed

Jung SH, Kim K, Kim JS, Kim SJ, Cheong JW, Kim SJ, et al. A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. Br J Haematol. 2017;181(5):707–710 https://doi.org/10.1111/bjh.14701.CrossRefPubMed

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. https://doi.org/10.1200/jco.2013.54.8800.CrossRefPubMedPubMedCentral

10.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206–e217. https://doi.org/10.1016/s1470-2045(17)30189-4.CrossRefPubMed

11.

Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014;83:2203–23. https://doi.org/10.1016/j.ejrad.2014.09.012.CrossRefPubMed

12.

Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. (1)(8)F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2015;15:1–18. https://doi.org/10.1007/s10238-014-0308-3.CrossRefPubMed

13.

Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76. https://doi.org/10.1182/blood-2009-03-213280.CrossRefPubMedPubMedCentral

14.

Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1068–73. https://doi.org/10.1016/j.bbmt.2015.03.001.CrossRefPubMed

15.

Lapa C, Luckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014;5:7381–91. https://doi.org/10.18632/oncotarget.2290.CrossRefPubMedPubMedCentral

16.

Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414–21. https://doi.org/10.1007/s00259-015-3200-9.CrossRefPubMed

17.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed

18.

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95. https://doi.org/10.1182/blood-2011-06-361386.CrossRefPubMed

19.

Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. https://doi.org/10.2967/jnumed.112.106500.CrossRefPubMed

20.

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23:1981–7. https://doi.org/10.1158/1078-0432.Ccr-16-0235.CrossRefPubMed

21.

Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, et al. Clinical utility of the revised international staging system in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017;7:e528. https://doi.org/10.1038/bcj.2017.13.CrossRefPubMedPubMedCentral

22.

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819–23. https://doi.org/10.1182/blood-2012-08-451690.CrossRefPubMedPubMedCentral

23.

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30–4. https://doi.org/10.1182/blood-2017-03-774422.CrossRefPubMedPubMedCentral

Titel: 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System
verfasst von: Sung-Hoon Jung
Seong Young Kwon
Jung-Joon Min
Hee-Seung Bom
Seo-Yeon Ahn
Seung-Yeon Jung
Seung-Shin Lee
Moo-Rim Park
Deok-Hwan Yang
Jae-Sook Ahn
Hyeoung-Joon Kim
Je-Jung Lee
Publikationsdatum: 05.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4114-0

Springer Medizin

Abstract

Purpose

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone

Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine

William T. O’Brien Sr. Top 3 Differentials in Radiology. A Case Review

FDG-PET imaging to detect and characterize underlying causes of fever of unknown origin: an unavoidable path for the foreseeable future

Value proposition of PSMA-targeted α–particle radioligand therapy in metastatic prostate cancer

Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer